Global R&D Pipeline
My Favorite
Hot Targets:
HER2
Back
Total number of drugs
896
Phase II and later clinical stages
11.5%
Involving companies
1040
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pyrotinib Maleate | Pyrotinib Maleate | Small molecule drug | Neoplasms Skin and Musculoskeletal Diseases Respiratory Diseases Digestive System Disorders | EGFR antagonists HER2 antagonists HER4 antagonists | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Jiangsu Hengrui Pharmaceuticals Co., Ltd. Dr. Reddy's Laboratories Ltd. | Approved | Approved | China | 2018-08-12 | 2018-08-12 | Breakthrough Therapy（China） Priority Review（China） Special Review Project（China） Conditional marketing approval（China） | - | - | - | - | Pyrotinib Maleate | - | - | detail > | |
| Trastuzumab/Pertuzumab/Hyaluroniase-zzxf | Trastuzumab/Pertuzumab/Hyaluroniase-zzxf | Monoclonal antibody Enzyme | Neoplasms Digestive System Disorders Skin and Musculoskeletal Diseases | HER2 antagonists Hyaluronic acid modulators ADCC | F. Hoffmann-La Roche Ltd. | Roche Pharma AG Chugai Pharmaceutical Co., Ltd. F. Hoffmann-La Roche Ltd. Roche Registration GmbH Hoffmann-La Roche, Inc. Hoffmann-La Roche Ltd. Genentech, Inc. Roche China Holding Ltd. Roche Pharma (Schweiz) AG | Approved | Approved | United States China European Union Japan Canada Iceland Liechtenstein Norway | 2020-06-29 | 2023-12-26 | - | - | - | - | - | Trastuzumab/Pertuzumab/Hyaluroniase-zzxf | - | - | detail > | |
| Tucatinib | Tucatinib | Small molecule drug | Neoplasms Digestive System Disorders Skin and Musculoskeletal Diseases Other Diseases Nervous System Diseases Respiratory Diseases Urogenital Diseases | HER2 antagonists | Array BioPharma, Inc. | Corden Pharma GmbH Genentech, Inc. MSD R&D (China) Co. Ltd. Seagen, Inc. Pfizer Australia Pty Ltd. Pieris Pharmaceuticals, Inc. Pfizer Inc. CRITERIUM, Inc. Merck Sharp & Dohme Corp. Pfizer Europe MA EEIG Merck & Co., Inc. | Approved | Phase 3 | United States European Union United Kingdom Canada Australia Switzerland Iceland Liechtenstein Norway Singapore | 2020-04-17 | - | Accelerated Approval（United States） Breakthrough Therapy（United States） Fast Track（United States） Orphan Drug（United States） Priority Review（Australia） Priority Review（United States） | - | - | - | - | Tucatinib | - | - | detail > | |
| Fam-trastuzumab deruxtecan-NXKI | Fam-trastuzumab deruxtecan-NXKI | Antibody drug conjugate (ADC) | Neoplasms Digestive System Disorders Respiratory Diseases Skin and Musculoskeletal Diseases Nervous System Diseases Endocrinology and Metabolic Disease Urogenital Diseases Other Diseases | HER2 antagonists TOP1 inhibitors ADCC | Daiichi Sankyo Co., Ltd. | AstraZeneca PLC Daiichi Sankyo Co., Ltd. AstraZeneca AB AstraZeneca Investment (China) Co. Ltd. Daiichi Sankyo, Inc. Daiichi Sankyo Europe GmbH Daiichi Sankyo UK Ltd. AstraZeneca Pty Ltd. Daiichi Sankyo (China) Holdings Co., Ltd. AstraZeneca Canada, Inc. AstraZeneca Pharmaceuticals LP | Approved | Approved | United States China European Union Japan United Kingdom Canada Australia India Israel Iceland South Korea Liechtenstein Norway | 2019-12-20 | 2023-02-21 | Accelerated Approval（United States） Breakthrough Therapy（China） Breakthrough Therapy（United States） Fast Track（United States） Orphan Drug（Australia） Orphan Drug（United States） Priority Review（Australia） Priority Review（China） Priority Review（United States） SAKIGAKE（Japan） Conditional marketing approval（China） Orphan Drug（Japan） | Trastuzumab | MC-GGFG | DXd | 8 | Fam-trastuzumab deruxtecan-NXKI | IgG1 - kappa | cysteinyl | detail > | |
| Trastuzumab/Hyaluronidase | Trastuzumab/Hyaluronidase | Monoclonal antibody Enzyme | Neoplasms Skin and Musculoskeletal Diseases | HER2 antagonists Hyaluronic acid modulators ADCC | Roche Holding AG | Halozyme Therapeutics, Inc. Genentech, Inc. | Approved | - | United States | 2019-02-28 | - | - | - | - | - | - | Trastuzumab/Hyaluronidase | - | - | detail > | |
| ADO-Trastuzumab Emtansine | ADO-Trastuzumab Emtansine | Antibody drug conjugate (ADC) | Neoplasms Skin and Musculoskeletal Diseases Digestive System Disorders Endocrinology and Metabolic Disease Mouth and Tooth Diseases Respiratory Diseases Urogenital Diseases | HER2 antagonists Tubulin inhibitors ADCC | Genentech, Inc. | DSM Pharmaceuticals, Inc. Hoffmann-La Roche Ltd. F. Hoffmann-La Roche Ltd. Hoffmann-La Roche, Inc. Shanghai Roche Pharmaceuticals Ltd. Genentech, Inc. Roche Registration GmbH Roche Pharma (Schweiz) AG Chugai Pharmaceutical Co., Ltd. Roche China Holding Ltd. Roche Registration Ltd. Roche Products Pty Ltd. | Approved | Approved | United States China European Union Japan Australia Iceland Liechtenstein Norway | 2013-02-22 | 2020-01-21 | Breakthrough Therapy（United States） Fast Track（United States） Priority Review（Australia） Priority Review（China） | Trastuzumab | MCC | Maytansinoid DM1 | 3 - 4 | ADO-Trastuzumab Emtansine | IgG1 - kappa | lysyl | detail > | |
| Mifanertinib Maleate | Mifanertinib Maleate | Small molecule drug | Neoplasms Respiratory Diseases | EGFR antagonists HER2 antagonists | Suzhou Maitai Bio-Technology Co., Ltd. | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Approved | Approved | China | 2025-10-21 | 2025-10-21 | Breakthrough Therapy（China） | - | - | - | - | Mifanertinib Maleate | - | - | detail > | |
| Pertuzumab | Pertuzumab | Monoclonal antibody | Neoplasms Digestive System Disorders Skin and Musculoskeletal Diseases Endocrinology and Metabolic Disease Hemic and Lymphatic Diseases Mouth and Tooth Diseases Respiratory Diseases Urogenital Diseases Nervous System Diseases Other Diseases | HER2 antagonists ADCC | Genentech, Inc. | Shanghai Roche Pharmaceuticals Ltd. Roche China Holding Ltd. F. Hoffmann-La Roche Ltd. Genentech, Inc. Hoffmann-La Roche, Inc. Roche Diagnostics GmbH Roche Registration GmbH Celgene Corp. Roche Products Pty Ltd. Novartis Pharmaceuticals Corp. Eisai GmbH Chugai Pharmaceutical Co., Ltd. Roche Pharma (Schweiz) AG Roche Pharma AG | Approved | Approved | United States China European Union Japan Australia Iceland Liechtenstein Norway | 2012-06-08 | 2018-12-17 | Accelerated Approval（United States） Orphan Drug（United States） | - | - | - | - | Pertuzumab | - | - | detail > | |
| Trastuzumab Botidotin | Trastuzumab Botidotin | Antibody drug conjugate (ADC) | Neoplasms Skin and Musculoskeletal Diseases Digestive System Disorders Respiratory Diseases | HER2 antagonists Tubulin inhibitors ADCC | Sichuan Kelun Pharmaceutical Co., Ltd. KLUS Pharma, Inc. | Sichuan Kelun Botai Biomedicine Co., Ltd. Levena Biopharma US, Inc. | Approved | Approved | China | 2025-10-14 | 2025-10-14 | - | Trastuzumab | Val-Cit | Duostatin 5 | 2 | Trastuzumab Botidotin | IgG1 - kappa | lysyl | detail > | |
| Neratinib maleate | Neratinib maleate | Small molecule drug | Neoplasms Skin and Musculoskeletal Diseases Nervous System Diseases Digestive System Disorders Respiratory Diseases Other Diseases Eye Diseases | EGFR antagonists HER2 antagonists HER4 antagonists | Pfizer Inc. | Celcuity, Inc. Puma Biotechnology, Inc. Pierre Fabre Médicament SAS Zhejiang Fukang Pharmaceutical Co., Ltd. Convalife (Shanghai) Co. Ltd. Pharmaceutical Biotechnology Qidong Co. Ltd. National Comprehensive Cancer Network, Inc. Bixink, Inc. Specialised Therapeutics Australia Pty Ltd. Knight Therapeutics, Inc. Pierre Fabre Pharma GmbH | Approved | Approved | United States China European Union Canada Australia Switzerland Iceland South Korea Liechtenstein Norway | 2017-07-17 | 2020-04-27 | Fast Track（United States） Orphan Drug（United States） | - | - | - | - | Neratinib maleate | - | - | detail > |
Total 896 data
1
2
3
4
5
6
...
89
90
